8-K: Revvity Anticipates Strong Q4 Revenue Growth and Full Year Earnings to Exceed Guidance

Revvity expects approximately 5% reported and 6% organic revenue growth for the fourth quarter of 2024, with full-year adjusted earnings per share meeting or exceeding prior guidance.

Summary

• Revvity anticipates a strong finish to 2024, with preliminary fourth-quarter revenue expected to reach approximately $730 million.
• The company projects a 5% reported revenue growth and a 6% organic revenue growth for the fourth quarter compared to the same period last year.
• Full-year 2024 adjusted earnings per share are now expected to meet or exceed the guidance previously provided on November 4, 2024.
• Revvity will release its full fourth quarter and full year 2024 financial results on January 31, 2025, prior to market open.
• A conference call to discuss these results will be held on the same day at 8:00 a.m. ET.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with strong revenue growth and earnings expected to exceed guidance. The company's strategic positioning and focus on innovation also contribute to a positive sentiment.

Positives

• The company is experiencing strong revenue growth in the fourth quarter.
• Full-year earnings are expected to be better than or in line with previous guidance.
• Revvity has a high percentage of recurring revenue, approximately 80%.
• The company is well-positioned in high-growth markets.
• Revvity is focused on innovation and customer satisfaction.
• The company has a differentiated financial profile with attractive margin expansion potential.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties.
• Actual results could differ materially from the projections due to various factors.
• The company's non-GAAP financial measures have limitations and should be viewed in conjunction with GAAP measures.
• The company's future performance is dependent on the level of organic growth.

Future Outlook

The company anticipates continued growth and margin expansion, with formal 2025 guidance to be provided during the earnings call on January 31st.

Management Comments

• Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call to discuss the results.
• Management believes that non-GAAP financial measures provide additional means of evaluating period-over-period operating performance.

Industry Context

Revvity operates in the life sciences and diagnostics sectors, which are experiencing growth due to advancements in research, drug development, and precision medicine. The company's focus on specialized, high-growth markets aligns with industry trends.

Comparison to Industry Standards

• Revvity's 5-year historical average organic growth for Life Sciences is HSD, which is above the market average.
• Revvity's 5-year historical average organic growth for Diagnostics is MSD, which is in line with the market average.
• The company's adjusted operating margin for Life Sciences is expected to be approximately 33% in 2024E, which is competitive with other companies in the sector.
• The company's adjusted operating margin for Diagnostics is expected to be approximately 27% in 2024E, which is competitive with other companies in the sector.

Stakeholder Impact

• Shareholders can expect positive news with the company's strong financial performance.
• Employees may benefit from the company's growth and success.
• Customers can expect continued innovation and high-quality products and services.

Next Steps

• Revvity will release its full fourth quarter and full year 2024 financial results on January 31, 2025.
• The company will host a conference call on January 31, 2025, to discuss the results.
• Formal 2025 guidance will be provided during the earnings call on January 31st.

Key Dates

Keywords

revenue growth, earnings per share, financial results, organic growth, life sciences, diagnostics, healthcare, non-GAAP, adjusted earnings, preliminary results